Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Upcoming efficacy % @360-days
View:
Post by ScienceFirst on Aug 24, 2022 11:42am

Upcoming efficacy % @360-days

Lets now focus on the 360-days milestone.  For the TR (CR + PR), we currently stand at 39%.
 
Now, 
 
... if 4 patients out of these 18 pending turn CR @360-days, then 13 (5 + 4 + 4) out of 41 patients = 32% @360-days 
... if 5 patients out of these 18 pending turn CR @360-days, then 14 (5 + 4 + 5) out of 41 patients = 34% @360-days
... if 6 patients out of these 18 pending turn CR @360-days, then 15 (5 + 4 + 6) out of 41 patients = 37% @360-days
... if 7 patients out of these 18 pending turn CR @360-days, then 16 (5 + 4 + 7) out of 41 patients = 39% @360-days
... if 8 patients out of these 18 pending turn CR @360-days, then 17 (5 + 4 + 8) out of 41 patients = 41% @360-days
... if 9 patients out of these 18 pending turn CR @360-days, then 18 (5 + 4 + 9) out of 41 patients = 44% @360-days
... if 10 patients out of these 18 pending turn CR @360-days, then 19 (5 + 4 + 10) out of 41 patients = 46% @360-days
... if 11 patients out of these 18 pending turn CR @360-days, then 20 (5 + 4 + 11) out of 41 patients = 49% @360-days
... if 12 patients out of these 18 pending turn CR @360-days, then 21 (5 + 4 + 12) out of 41 patients = 51% @360-days
... if 13 patients out of these 18 pending turn CR @360-days, then 22 (5 + 4 + 13) out of 41 patients = 54% @360-days
... if 14 patients out of these 18 pending turn CR @360-days, then 23 (5 + 4 + 14) out of 41 patients = 56% @360-days
... if 15 patients out of these 18 pending turn CR @360-days, then 24 (5 + 4 + 15) out of 41 patients = 59% @360-days
... if 16 patients out of these 18 pending turn CR @360-days, then 25 (5 + 4 + 16) out of 41 patients = 61% @360-days
... if 17 patients out of these 18 pending turn CR @360-days, then 26 (5 + 4 + 17) out of 41 patients = 63% @360-days
... if 18 patients out of these 18 pending turn CR @360-days, then 27 (5 + 4 + 18) out of 41 patients = 66% @360-days
 
Comment by enriquesuave on Aug 24, 2022 12:27pm
With 2nd treatment if we can maintain a similar 360 and 450 day efficacy as at 90 days ( even slightly lower), then we are by far the best option.  Exciting next few weeks/ months for sure.
Comment by Rumpl3StiltSkin on Aug 24, 2022 12:53pm
Agree, Things well become very clear in the coming months.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250